Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort
Year: 2026
Type: article
Abstract: Background: Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control. Methods: We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation). Results: Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40). Conclusions: In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.
Source: Antibiotics
Authors: Andrea Marino, Emmanuele Venanzi Rullo, Giuseppe Pipitone, Alessandro Giorgio Geremia, Andrea De Vito, Antonio Albanese, Nicholas Geremia, Alessandro Franzò, Barbara Bellocchi, Eugenia Pistarà, Paolo Italia, Bianca Catania, Andrea Buzzi, Laura Santoro, Serena Spampinato, Chiara Iaria, Giordano Madeddu, Carmelo Iacobello, Rosa Manuele, Fabrizio Pulvirenti, Bruno Cacopardo, Giuseppe Nunnari
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: dalbavancin, oritavancin, device-related infection, periprosthetic joint infection, prosthetic valve endocarditis, surgical source control, day hospital, Gram-positive bacterial infections, C-reactive protein, adverse drug reactions, clinical success, acute bacterial skin and skin structure infections
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236097344
